Latest Antisense News

Light Switch Added to Oligomers Improves Precision of Gene-Blocking StudiesScientists collaborating with a company that synthesizes antisense oligomers have tested a new Ultraviolet light-activated on-off switch linked...

Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 MeetingCARLSBAD, Calif., May 23 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Data from KYNAMRO™ presented at EAS 2012

Antisense therapeutics: New ways to nudge splicingDuplexes formed between pre-mRNA and 2′-fluorinated oligonucleotides suppress nearby splice sites by recruiting double-stranded RNA–binding proteins.

Bio-Path Holdings Reports First Quarter 2012 Operational and Financial ResultsBio-Path Holdings, Inc. (OTC BB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the quarter ended March 31, 2012. FIRST QUARTER 2012 OPERATIONAL AND FINANCIAL HIGHLIGHTS Recent Operational Highlights...

Isis Pharmaceuticals to Present A General Corporate Update at Its 2012 Annual Meeting of Stockholders and Open HouseCARLSBAD, Calif., May 14, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2012 Annual Meeting of Stockholders and Open House on Thursday, June 7 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows:2:00 p.m. ̵...

Antisense Pharma Internationalizes Management Board

Dr. Philippe Calais appointed Chief Executive Officer (CEO) Regensburg, Germany, May 10, 2012 / B3C newswire / - The biopharmaceutical company Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies – including Hofmann La-...

RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive OfficerRXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Geert Cauwenbergh, Dr. Med. Sc. has been appointed as the Company’s President and Chief Executive Officer. Dr. Cauwenbergh brings more than 30 years of experience in the pharmaceutical industry, including a successful track record developing and commercializing dermatological drugs. Dr...

Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care ConferenceCARLSBAD, Calif., May 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America Merrill Lynch's 2012 Health Care Conference on Tuesday, May 15, 2012 at 2:20 p.m. PT at the Encore at the Wynn in Las Vegas, NV. A live audio webcast of the presentation will be...

Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease(Halsin Partners) Gene Signal's aganirsen, an antiangiogenic antisense product targeting IRS-1, shows activity in retinal disease, according to data presented at ARVO2012.

RNF12 initiates X-chromosome inactivation by targeting REX1 for degradationEvolution of the mammalian sex chromosomes has resulted in a heterologous X and Y pair, where the Y chromosome has lost most of its genes. Hence, there is a need for X-linked gene dosage compensation between XY males and XX females. In placental mamm...

Webcast Alert: Isis Pharmaceuticals' First Quarter 2012 Financial Results Conference CallCARLSBAD, Calif., April 25, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2012 Financial Results Conference Call

RNAi, MiRNA & SiRNA: A Focus On Nanotechnology & DeliveryConference, 11-12 June 2012, LondonSMi present their annual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference on 11th &12th June 2012 held in London. This year's event will focus on the utility of nanotechnology to aid the delivery and development of novel therapeut...

AVI BioPharma to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 AAN Annual Meeting BOTHELL, WA -- (Marketwire) -- 04/25/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced that data from a Phase IIb study evaluating eteplirsen as a treatment for boys with Duchenne muscular dystrophy (DMD) will be presented today at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana. Principal investigator, Jerry R. Mendell, M....

Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRxCARLSBAD, Calif., April 18, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: What:

Spatial partitioning of the regulatory landscape of the X-inactivation centreIn eukaryotes transcriptional regulation often involves multiple long-range elements and is influenced by the genomic environment. A prime example of this concerns the mouse X-inactivation centre (Xic), which orchestrates the initiation of X-chromoso...

Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer

Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial ResultsBio-Path Holdings, Inc., (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2011. 2011 OPERATIONAL AND FINANCIAL HIGHLIGHTS Recent Operational Highlights...

Light switch added to gene tool opens new view of cell development(University of Oregon) University of Oregon scientists collaborating with an Oregon company that synthesizes antisense Morpholinos for genetic research have developed a UV light-activated on-off switch for the vital gene-blocking molecule. Based on i...

AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of Duchenne Muscular Dystrophy BOTHELL, WA -- (Marketwire) -- 04/02/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy (DMD). Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistica...

Isis Pharmaceuticals to Present at the 11th Annual Needham Healthcare ConferenceCARLSBAD, Calif., March 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Needham's 11th Annual Healthcare Conference on Tuesday, April 03, 2012 at 11:20 a.m. ET at the New York Palace Hotel. A live audio webcast of the presentation will be available on the "Investors &a...

Data From AVI BioPharma's Infectious Disease Programs to Be Presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases BOTHELL, WA -- (Marketwire) -- 03/30/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the presentation of data from the Company's infectious disease programs at the 22nd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in London, United Kingdom from March 31 to April 3. These programs utilize a common...

Bio-Path Holdings Engages PondelWilkinson for Retail Investor Relations ProgramBio-Path Holdings, Inc., (OTCBB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has entered into a services agreement with Los Angeles-based investor relations firm PondelWilkinson to assist the Company in implementing an investor and public relations program...

Genzyme submits Kynamro NDAGenzyme Corp. submitted an NDA to FDA for Kynamro mipomersen to treat homozygous familial hypercholesterolemia (hoFH). Partner Isis Pharmaceuticals Inc. (NASDAQ:ISIS) is eligible for a $25 million milestone payment from Genzyme upon FDA acceptance. G...

Almac and Affymetrix Announce a Global Distribution Agreement for Almac’s Xcel™ ArrayAlmac today announced that it has signed an exclusive global distribution deal with Affymetrix, Inc. enabling them to directly sell Almac’s proprietary Xcel™ array for biomarker discovery, development and delivery worldwide. Almac’s Xcel™ array i

Affymetrix Announces a Global Distribution Agreement With Almac to Distribute Its Proprietary Xcel™ Array for Translational Research ApplicationsAffymetrix, Inc. (NASDAQ:AFFX) today announced that it has signed a global distribution agreement with Almac Group Ltd., an established company that provides an extensive range of pharmaceutical services. In this agreement, Affymetrix has exclusive rights to distribute Almac’s

0 1 2 3 4 ›»

buy Antisense market research data and corporate reports now Advertisement